

Jose M Olivares

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7556545/jose-m-olivares-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71
papers

1,415
citations

22
h-index

35
g-index

96
ext. papers

1,687
ext. citations

2.9
avg, IF

4.3
L-index

#	Paper	IF	Citations
71	Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 850583	5.6	1
70	Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 877867	5	
69	Efficacy of the Therapeutic Game "Trisquel" in the Treatment of Patients With Substance-Related Disorders Randomized Clinical Study.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 864511	5	
68	Early intervention services, patterns of prescription and rates of discontinuation of antipsychotic treatment in first-episode psychosis. <i>Microbial Biotechnology</i> , 2021 , 15, 1584-1594	3.3	0
67	Changes in the Brain Extracellular Matrix Composition in schizophrenia: A Pathophysiological Dysregulation and a Potential Therapeutic Target. <i>Cellular and Molecular Neurobiology</i> , 2021 , 1	4.6	2
66	Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 1887-1892	3.1	1
65	Perfil proteómico y metabólico de pacientes crónicos con esquizofrenia tras un programa de actividad física: estudio piloto. <i>Revista De Psiquiatría Y Salud Mental</i> , 2021 , 14, 125-138	2.7	
64	Proteomic and metabolic profiling of chronic patients with schizophrenia induced by a physical activity program: Pilot study. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2021 , 14, 125-138	0.2	
63	Important role of microglia in HIV-1 associated neurocognitive disorders and the molecular pathways implicated in its pathogenesis. <i>Annals of Medicine</i> , 2021 , 53, 43-69	1.5	18
62	Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study. <i>European Psychiatry</i> , 2021 , 64, e40	6	0
61	Microglia: The Real Foe in HIV-1-Associated Neurocognitive Disorders?. <i>Biomedicines</i> , 2021 , 9,	4.8	1
60	The Role of the Second Extracellular Loop of Norepinephrine Transporter, Neurotrophin-3 and Tropomyosin Receptor Kinase C in T Cells: A Peripheral Biomarker in the Etiology of Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
59	Mania as Debut of Cushing's Syndrome. <i>Case Reports in Psychiatry</i> , 2020 , 2020, 9127632	0.6	1
58	A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine. <i>Frontiers in Psychiatry</i> , 2020 , 11, 554899	5	4
57	Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report. <i>Frontiers in Pharmacology</i> , 2020 , 11, 557629	5.6	13
56	Plasma β III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia. <i>Scientific Reports</i> , 2020 , 10, 14271	4.9	8
55	Brainwaves Oscillations as a Potential Biomarker for Major Depression Disorder Risk. <i>Clinical EEG and Neuroscience</i> , 2020 , 51, 3-9	2.3	12

54	Improving emotion recognition in schizophrenia with "VOICES": An on-line prosodic self-training. <i>PLoS ONE</i> , 2019 , 14, e0210816	3.7	13
53	CIBERSAM: Ten years of collaborative translational research in mental disorders. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2019 , 12, 1-8	0.2	1
52	Patterns of Membrane Protein Clustering in Peripheral Lymphocytes as Predictors of Therapeutic Outcomes in Major Depressive Disorder. <i>Frontiers in Pharmacology</i> , 2019 , 10, 190	5.6	5
51	Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. <i>Revista De Psiquiatría Y Salud Mental</i> , 2019 , 12, 92-105	2.7	11
50	Proteomics in Schizophrenia: A Gateway to Discover Potential Biomarkers of Psychoneuroimmune Pathways. <i>Frontiers in Psychiatry</i> , 2019 , 10, 885	5	9
49	Assessment of adherence to treatment with injectable extended-release antipsychotics within a pharmacotherapeutic follow-up program. <i>Farmacia Hospitalaria</i> , 2019 , 43, 177-181	0.9	
48	The role of the gut microbiota in schizophrenia: Current and future perspectives. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 571-585	3.8	24
47	Cytokines dysregulation in schizophrenia: A systematic review of psychoneuroimmune relationship. <i>Schizophrenia Research</i> , 2018 , 197, 19-33	3.6	49
46	The neurobiological hypothesis of neurotrophins in the pathophysiology of schizophrenia: A meta-analysis. <i>Journal of Psychiatric Research</i> , 2018 , 106, 43-53	5.2	24
45	Changes in Membrane Protein Clustering in Peripheral Lymphocytes in an Animal Model of Depression Parallel Those Observed in Naïve Depression Patients: Implications for the Development of Novel Biomarkers of Depression. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1149	5.6	4
44	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017 , 10, 4-20	2.7	11
43	Schizophrenia: A review of potential biomarkers. <i>Journal of Psychiatric Research</i> , 2017 , 93, 37-49	5.2	30
42	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2017 , 10, 4-20	0.2	
41	Comparative study of two protocols for quantitative image-analysis of serotonin transporter clustering in lymphocytes, a putative biomarker of therapeutic efficacy in major depression. <i>Biomarker Research</i> , 2017 , 5, 27	8	6
40	Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. <i>BMC Psychiatry</i> , 2017 , 17, 250	4.2	100
39	Reelin-Related Disturbances in Depression: Implications for Translational Studies. <i>Frontiers in Cellular Neuroscience</i> , 2016 , 10, 48	6.1	32
38	Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors. <i>Annals of General Psychiatry</i> , 2015 , 14, 2	3.4	6
37	Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms. <i>International Clinical Psychopharmacology</i> , 2015 , 30, 265-71	2.2	6

36	Serotonin transporter clustering in blood lymphocytes predicts the outcome on anhedonia scores in naïve depressive patients treated with antidepressant medication. <i>Annals of General Psychiatry</i> , 2015 , 14, 45	3.4	11
35	Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 4329-40	4.4	5
34	Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey. <i>Therapeutic Advances in Psychopharmacology</i> , 2015 , 5, 339-50	4.9	9
33	Pellagra encephalopathy in the context of alcoholism: review and case report. <i>Alcohol and Alcoholism</i> , 2014 , 49, 38-41	3.5	17
32	Serotonin 2A receptor clustering in peripheral lymphocytes is altered in major depression and may be a biomarker of therapeutic efficacy. <i>Journal of Affective Disorders</i> , 2014 , 163, 47-55	6.6	25
31	Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2013 , 48, 985-96	4.5	6
30	Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. <i>Annals of General Psychiatry</i> , 2013 , 12, 32	3.4	128
29	Improving treatment adherence in your patients with schizophrenia: the STAY initiative. <i>Clinical Drug Investigation</i> , 2013 , 33, 97-107	3.2	33
28	Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa. <i>Patient Preference and Adherence</i> , 2013 , 7, 121-32	2.4	20
27	Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific survey. <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 1163-70	3.1	12
26	Serotonin transporter clustering in blood lymphocytes as a putative biomarker of therapeutic efficacy in major depressive disorder. <i>Journal of Affective Disorders</i> , 2012 , 137, 46-55	6.6	25
25	Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012 , 36, 245-50	5.5	13
24	Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain. <i>ClinicoEconomics and Outcomes Research</i> , 2012 , 4, 157-68	1.7	6
23	Broadening of Generalized Anxiety Disorders Definition Does not Affect the Response to Psychiatric Care: Findings from the Observational ADAN Study. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2012 , 8, 158-68	3.2	8
22	Treatment patterns and health care resource utilization in a 1-year observational cohort study of outpatients with schizophrenia at risk of nonadherence treated with long-acting injectable antipsychotics. <i>Patient Preference and Adherence</i> , 2011 , 5, 601-10	2.4	3
21	Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. <i>Annals of General Psychiatry</i> , 2011 , 10, 10	3.4	36
20	Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia. <i>Neuropsychiatry</i> , 2011 , 1, 275-289	1.8	19
19	Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. <i>Current Medical Research and Opinion</i> , 2010 , 26, 501-9	2.5	51

18	Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. <i>Current Medical Research and Opinion</i> , 2009 , 25, 2197-206	2.5	47
17	Tratamiento de la catatonia letal con antipsicóticos atípicos: a propósito de un caso. <i>Psiquiatría Biológica</i> , 2009 , 16, 42-45	0.2	0
16	Management of patients presenting with acute psychotic episodes of schizophrenia. <i>CNS Drugs</i> , 2009 , 23, 193-212	6.7	30
15	Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). <i>European Psychiatry</i> , 2009 , 24, 287-96	6	118
14	Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. <i>Applied Health Economics and Health Policy</i> , 2008 , 6, 41-53	3.4	56
13	Clinical characteristics of agitated psychotic patients treated with an oral antipsychotics attended in the emergency room setting: NATURA study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2008 , 12, 127-33	2.4	2
12	A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. <i>International Journal of Neuropsychopharmacology</i> , 2008 , 11, 445-52	5.8	54
11	An analysis of the cognitive deficit of schizophrenia based on the Piaget developmental theory. <i>Comprehensive Psychiatry</i> , 2007 , 48, 376-9	7.3	5
10	Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. <i>European Neuropsychopharmacology</i> , 2007 , 17, 725-34	1.2	11
9	Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006 , 30, 1515-22	5.5	13
8	A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 238-49	1.7	42
7	Subjective perception of cognitive deficit in psychotic patients. <i>Journal of Nervous and Mental Disease</i> , 2006 , 194, 58-60	1.8	11
6	Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005 , 29, 972-82	5.5	23
5	Validation of the Spanish version of the Social Functioning Scale. <i>Actas Espanolas De Psiquiatría</i> , 2005 , 33, 216-20	0.7	14
4	Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study. <i>European Psychiatry</i> , 2004 , 19, 358-65	6	9
3	1-year follow-up of patients treated with risperidone and topiramate for a manic episode. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 834-9	4.6	24
2	The anhedonias: Clinical and neurobiological aspects. <i>International Journal of Psychiatry in Clinical Practice</i> , 1998 , 2, 157-71	2.4	9
1	The anhedonias: a conceptual history. <i>History of Psychiatry</i> , 1995 , 6, 453-70	0.6	20

